• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » melanoma

Articles Tagged with ''melanoma''

FDA clears first TIL therapy as Iovance wins accelerated nod in melanoma

Feb. 20, 2024
By Jennifer Boggs
Roughly 35 years after early patient data suggested the potential of tumor-infiltrating lymphocytes (TIL) in cancer, Iovance Biotherapeutics Inc. received U.S. FDA approval for lifileucel, marking both the first autologous TIL cell therapy for commercial use and the first one-time cell therapy for a solid tumor cancer. Branded Amtagvi, lifileucel is cleared for use in patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation-positive, a BRAF inhibitor with or without a MEK inhibitor
Read More
Cancer cells
Immuno-oncology

Cytomx receives IND clearances for CX-2051 and CX-801

Jan. 25, 2024
Cytomx Therapeutics Inc. has received clearances from the FDA for IND applications for two conditionally activated Probody therapeutics.
Read More
Cancer

TCF4 genetic network behind melanoma resistance to immune checkpoint blockade

Jan. 16, 2024
Although treatment outcomes have improved in metastatic melanoma since the use of immune checkpoint blockade (ICB), it still remains a medical challenge. Melanoma cells are thought to adapt several phenotypic states, such as mesenchymal-like state (MES), which may modulate their sensitivity to therapy. An international team of researchers has now investigated the mechanisms behind melanoma cells’ resistance to ICB.
Read More
MLA LY75 mathylation kit

New funding brightens prognosis for MLA Diagnostics

Dec. 15, 2023
By Annette Boyle
MLA Diagnostics BV secured a strategic seven-figure investment in its recent investment round to support external validation of the company’s melanoma prognosis test. Co-founders NLC Health Ventures and Brightlands Life Sciences Ventures participated in the round along with LIOF, the regional development organization for the Limburg province of the Netherlands.
Read More

Replimune’s lead candidate misses two phase II endpoints

Dec. 5, 2023
By Lee Landenberger
Replimune Group Inc.’s lead candidate, RP-1 (vusolimogene oderparepvec), took a solid hit as it missed both primary endpoints in the Cerpass phase II study of skin cancer. Despite some better results from the study and good news from other studies along with a plan to drop some programs, the company’s stock still suffered.
Read More
Immuno-oncology

New ADC option to treat rare melanoma subtypes divulged

Dec. 1, 2023
Researchers from Multitude Therapeutics Inc. have reported the preclinical profile of AMT-253, a MUC18-targeting antibody-drug conjugate (ADC) under development for the treatment of melanoma. It comprises the anti-MUC18 humanized antibody pAb253-H linked to T1000 exatecan payload and showed superior antitumor efficacy than the traditional vc-MMAE-based ADC AMT-253-M.
Read More
Gene editing illustration
Immuno-oncology

KSQ’s CRISPR/Cas9 eTIL therapy IND cleared by FDA

Nov. 30, 2023
KSQ Therapeutics Inc., in collaboration with The University of Texas MD Anderson Cancer Center and the Cell Therapy Manufacturing Center (CTMC), have announced FDA clearance of an IND application for a phase I/II study of KSQ-001EX, KSQ’s lead engineered tumor-infiltrating lymphocyte (eTIL) program.
Read More
Cancer cell, dropper, test tubes

Alkermes spinout Mural Oncology launches with lead IL-2 drug

Nov. 15, 2023
By Karen Carey
A year after Alkermes plc announced it would divide its oncology and neuroscience efforts into two separate businesses, the Dublin-based company spun out Mural Oncology plc with $275 million in funding and the lead solid tumor candidate nemvaleukin alfa. Shares of Mural (NASDAQ:MURA) will begin trading Nov. 16. “We’re very excited,” Mural’s CEO Caroline Loew told BioWorld. “We’ve got two major clinical datapoints in the next 18 months.”
Read More
Metastatic melanoma cells.
Cancer

Novel tricyclic BRD4 inhibitor for melanoma disclosed

Oct. 27, 2023
Protein bromodomain-containing protein 4 (BRD4) is involved in transcription, DNA replication and cell cycle among other processes, and its overexpression has been linked to several types of cancer and immune disorders.
Read More
Antibody-drug conjugate illustration
Immuno-oncology

HLX-43, a next-generation PD-L1-targeting antibody-drug conjugate

Oct. 27, 2023
There is a need for new agents targeting PD-1/PD-L1 because many patients either do not respond or develop resistance to treatment.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 12 … 16 17 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 29, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 29, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 29, 2025
  • Illustration of Microglia cells (red) in Alzheimer´s disease

    Two cancer drugs combined modify Alzheimer’s disease in mice

    BioWorld
    Current treatments for Alzheimer’s disease have limited effects. While they can slow cognitive decline or alleviate symptoms, they do not reverse this complex...
  • Opportunity compass with Chinese flag

    For big pharma, China is a shopper’s dream

    BioWorld
    Big pharma is increasingly shopping in China to fill its pipelines as it faces looming patent cliffs on major blockbusters coupled with growing pricing...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe